Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICSBR phase II trial of serplulimab + gemcitabine + nab-paclitaxel + SBRT in metastatic pancreatic adenocarcinoma
ChiCTR2300073237Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Primary endpoint: 6-month progression-free survival rate. Started Apr 2023; status: recruiting.
02
Drugs
serplulimabgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2300073237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073237.